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Abstract
The lung is an organ with a large inner surface that is continuously in contact with the environment. Infection of this organ
is prevented by several mechanisms. A recently described defence system is collectin-mediated innate immunity of the lung.
Collectins are multimeric proteins characterized by carbohydrate recognition domains bound to collagen stalks. Surfactant
protein (SP)-A and SP-D are collectins that are present in the epithelial lining fluid of the lung. SP-A interacts with viruses,
bacteria and fungi. Furthermore, SP-A binds to various other inhaled glycoconjugates. SP-A receptors on phagocytic cells
have been described that are important to ensure rapid pathogen clearance. This innate defence system of the lung may be
particularly important during infections in young children when the acquired immune system has not yet become fully
established. Also in later life SP-A could be very important to prevent the lungs from infections by pathogens not previously
encountered. In addition, SP-A may limit the inflammatory response in the lungs, thus preventing damage to the delicate
lung epithelia. Recently, evidence was presented that SP-A may modulate the allergic response to various glycosylated
inhaled antigens. The presence of SP-A (and SP-D) in other organs indicates that these collectins may have a general role in
mucosal immunity. In this review the interactions of SP-A with a variety of pathogens and its implications are
discussed. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Gas exchange in the lung takes place in the alveoli.
Pulmonary surfactant is a complex mixture of lipids
and proteins that forms a thin ¢lm at the air-water
interface of the alveoli and thus reduces the surface
tension. It protects the alveoli against collapse at
end-expiration, reduces the work of breathing, and
precludes alveolar oedema [1]. Furthermore, surfac-
tant components may have important functions in
innate lung defence. Isolated surfactant contains ap-
prox. 90% lipids and 10% proteins by weight. The
surfactant lipids are mainly phospholipids (95%), of
which phosphatidylcholine (PC) represents 70^80%.
The major phospholipid component of lung surfac-
tant is dipalmitoylphosphatidylcholine (DPPC),
which is responsible for the low surface tension at
end-expiration. Surfactant comprises two types of
surfactant proteins: SP-A and SP-D (large hydro-
philic proteins), and SP-B and SP-C (small hydro-
phobic proteins). SP-A and SP-D are related and
belong to a subgroup of mammalian lectins called
‘collectins’ (or C-type lectins, group III). These pro-
teins consist of oligomers with carboxy-terminal car-
bohydrate recognition domains bound via a ‘neck’
region to amino-terminal collagen-like domains. In
lung lavage most SP-A is associated with surfactant
lipids, whereas most SP-D is not. For both SP-A and
SP-D the main sites of synthesis and secretion are the
bronchiolar Clara cells and alveolar type II cells. In
Clara cells, SP-A and SP-D are present in secretory
granules [2], that could potentially be secreted in an
acute phase reaction upon an infectious challenge [3].
The fact that SP-A could be detected in tracheal and
bronchial glands, and in the epithelium of conduct-
ing airways [4], also suggests the importance of non-
surfactant-associated pulmonary functions of SP-A,
and contributes to the proposed role of SP-A in the
host defence of the lung. Indeed, accruing evidence
suggests that the most important functions of SP-A
and SP-D are their roles in host defence. Further-
more, SP-A may have a role in the structural organ-
ization of surfactant. In this review I will focus on
some of the properties of SP-A, its interactions with
various glycoconjugates and pathogens, and its puta-
tive functions in lung defence. The reader is referred
to the chapter of Tino and Wright in this issue for
information on the interactions of SP-A with epithe-
lial cells and phagocytes.
SP-A was the ¢rst of the surfactant proteins that
was puri¢ed [5], and analysed for its primary struc-
ture [6]. It is an abundant protein in bronchoalveolar
lavage and relatively easy to purify. Butanol extrac-
tion is a widely used method to purify SP-A, but it
has been reported that some of the functional char-
acteristics of SP-A are lost during this extraction
procedure [7]. The molecular mass of the monomeric
form is 28^36 kDa and human SP-A comprises
248 amino acid residues. The primary structure of
SP-A comprises four domains: an amino-terminal
domain, a collagenous domain, a neck domain and
a carbohydrate recognition domain (see [8] and the
chapter by McCormack in this issue for details). The
carbohydrate binding domain (CRD) contains a
Ca2-dependent speci¢c carbohydrate binding site.
The positions of the four cysteine residues in this
region are conserved in all members of the class of
calcium-dependent lectins. Disulphide bonds have
been described between residues 135 and 226, and
residues 204 and 218 [9]. The asparagine at position
187 of the CRD is N-glycosylated.
Because SP-A was the ¢rst surfactant-associated
protein discovered, the properties and putative func-
tions of SP-A were studied more extensively than
those of the other surfactant proteins. Obviously,
SP-A is not directly responsible for the surface ten-
sion lowering properties of pulmonary surfactant,
although SP-A has possibly a regulating role
[10,11]. It should be kept in mind that studies with
knock-out mice have shown that SP-A is not abso-
lutely required for breathing [12]. In a recent study
the surface properties, morphology and protein com-
position of surfactant subtypes were reported [13]. It
was found that surface ¢lm formation from di¡erent
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surfactant fractions was dependent on surfactant
structure. Interestingly, at low surfactant concentra-
tions extracted surfactants showed a delayed adsorp-
tion compared to natural surfactants, which suggests
that the SP-A-dependent structural organization is
important to ensure e⁄cient surface ¢lm formation.
In vivo, this structural organization is represented by
tubular myelin which is formed from lamellar bodies
after they have been secreted into the epithelial lining
£uid of the alveolar space. In vitro studies indicated
that tubular myelin formation depends on the pres-
ence of SP-A (and SP-B) [14]. In tubular myelin SP-
A has a preferential localization which suggests that
SP-A-SP-A interactions form the sca¡old of this
structure [15]. Tubular myelin may ful¢l a role in
vivo as an extracellular surfactant reservoir that is
not susceptible to inactivation by inhaled particles,
pathogens and transudated serum proteins. Thus,
SP-A may protect surfactant function under patho-
logical conditions.
2. Carbohydrate binding speci¢city of SP-A
The ¢rst indications that SP-A may have a role in
host defence were obtained 12 years ago. Drickamer
and co-workers described a sequence similarity be-
tween SP-A and mannose binding proteins, and sug-
gested that SP-A could also have carbohydrate-bind-
ing properties [16]. Shortly afterwards, calcium-
dependent binding of SP-A to monosaccharides was
described and it was proposed that SP-A may play a
role in the lung defence [17]. Two reasons were sup-
porting this notion: SP-A is able to bind carbohy-
drates, and SP-A is structurally similar to C1q [18].
In these early studies it was found that SP-A binds to
agarose-bound D-mannose, L-fucose, D-galactose and
D-glucose but not very well to N-acetyl-D-galactos-
amine and N-acetyl-D-glucosamine [17]. Under the
conditions employed, the threshold Ca2 concentra-
tion was 0.6 mM and maximal binding was observed
at 1 mM Ca2. Ba2, Sr2, and Mn2, but not Mg 2
could substitute for Ca2. Binding of 125I-labelled
SP-A to bovine serum albumin linked monosacchar-
ides showed similar binding characteristics [19].
In another study the carbohydrate-binding charac-
teristics of normal human SP-A and SP-A from al-
veolar proteinosis patients were compared with those
of mannan-binding protein (MBP) and conglutinin
in an enzyme-linked lectin-binding assay [20]. It
was found that several monosaccharides (in D-con¢g-
uration, except fucose of which both L- and D-con-
¢gurations were tested) competed for the binding of
SP-A to mannan from Saccharomyces cerevisiae. The
order of inhibiting potency was: N-acetylmannosa-
mines L-fucose = maltoses glucosesmannose (Fig.
1). Galactose, D-fucose, glucosamine, mannosamine,
galactosamine, N-acetylglucosamine, and N-acetylga-
lactosamine were non-inhibitory. The discrepancy
between this study and the earlier studies, especially
with respect to the a⁄nity for galactose, may be ex-
plained by the di¡erent binding assays employed. It
must be noted that the a⁄nities for mannose and
galactose may be mutually exclusive in C-type lec-
tins. According to the elegant studies of Drickamer
[21] with MBP and McCormack and co-workers [8]
with rat SP-A, mannose-binding speci¢city is deter-
mined by the motif Glu-Pro-Asn (Glu195-Pro196-
Arg197 in rat SP-A), whereas galactose-binding spe-
ci¢city is determined by the motif Gln-Pro-Asp.
Therefore, the observed binding of SP-A to immobi-
lized galactose may be an artifact, induced by the
coupling of the monosaccharide to agarose [17] or
to bovine serum albumin [19].
Childs and co-workers observed that human SP-A
binds in a Ca2-dependent fashion to the glycolipids
galactosyl ceramide and lactosyl ceramide [19]. The
binding of SP-A to glycolipids was dependent on the
Fig. 1. Carbohydrate binding speci¢city of SP-A. IC50, concen-
tration of the sugar resulting in a 50% reduction of the binding
to mannan-coated microtitre wells. Galactose, D-fucose, man-
nosamine, glucosamine, galactosamine, N-acetylglucosamine,
and N-acetylgalactosamine were not inhibitory. Data are taken
from [20].
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assay system (thin layer chromatograms vs. micro-
wells) and it was observed that SP-A binds both
saccharide and lipid moieties of glycolipids. Interest-
ingly, SP-A binds with a di¡erent a⁄nity to galacto-
syl ceramides that di¡er only in having either K-hy-
droxy or non-hydroxy fatty acids, an observation
later con¢rmed by Hynsjo« et al. with lactosyl ceram-
ides [22]. The apparent a⁄nities of SP-A for these
respective galactosyl ceramides were also dependent
on the assay system. This study showed again that
results of binding studies of SP-A to various ligands,
including cell surface ligands, should be interpreted
with caution. Another remark that can be made here
concerns the use of 125I-labelled SP-A in binding
studies. Several investigators have shown that radio-
iodination procedures readily inactivate SP-A [20,23],
probably because SP-A is extremely sensitive to ox-
idative stress [24]. It must be stressed that other
workers did not appear to experience problems using
radioiodinated SP-A. Nevertheless, one must be
aware that the fraction of total SP-A that has been
labelled may behave di¡erently from the unlabelled
SP-A in tests designed to screen for biological activ-
ities.
In a detailed study into the binding of 125I-SP-A to
glycolipids Kuroki and co-workers con¢rmed the
binding to galactosyl ceramides and the observation
that this binding involves both saccharide and lipid
moieties [25]. This ¢nding was corroborated by the
fact that SP-A did not bind to galactosylsphingosine.
No binding of SP-A was observed to glucosylcera-
mide, sulphatide, Forssman antigen, GM1, GM2, and
asialo-GM1. In addition to galactosyl ceramides,
SP-A bound to asialo-GM2. The oligosaccharide de-
rived from asialo-GM2 competed with the solid-phase
asialo-GM2 for SP-A binding [25]. Using native (not
iodinated) human SP-A Hynsjo« and collaborators
con¢rmed the work of Childs and Kuroki [22]. It is
not clear whether glycolipid binding of SP-A is in-
volved in defence mechanisms such as binding to
enveloped viruses and subsequent enhancement of
phagocytosis or prevention of epithelial binding
and entry of pathogens.
3. Interactions of SP-A with viruses
SP-A has been reported to act as an opsonin in the
phagocytosis of herpes simplex virus type 1 by rat
alveolar macrophages [26]. Compared to the opsonic
capacity of serum, SP-A was found to be twice as
potent. The SP-A-mediated phagocytosis of FITC-
labelled herpes simplex virus type 1 was time- and
concentration-dependent. Preincubation of the mac-
rophages with SP-A followed by neutralization of
cell-bound SP-A with F(abP)2 fragments of anti-
SP-A abolished herpes simplex virus type 1 phagocy-
tosis. SP-A binds herpes simplex virus type 1 as was
shown indirectly by the increased binding to virus-
infected HEp-2 cells expressing viral proteins at the
cell surface [27]. Binding of SP-A to infected cells
was inhibited by heparin, but not by yeast mannan.
Interestingly, deglycosylated SP-A, obtained by di-
gestion with N-glycosidase F, did not bind to in-
fected cells. These observations suggest that the car-
bohydrate moiety of SP-A is involved in recognition
of viruses [27]. The carbohydrate moiety of SP-A is
not required for stimulation of alveolar macrophages
since deglycosylated SP-A still stimulated the pro-
duction of free radicals by these cells. Furthermore,
heparin did not in£uence SP-A-mediated stimulation
of alveolar macrophages, suggesting that the molec-
ular requirements for virus binding di¡er from those
for binding to macrophages.
SP-A binds in£uenza virus A (H3N2) in a satura-
ble, concentration-dependent fashion in the presence
of Ca2 [28]. The binding of SP-A in the presence of
Ca2 to immobilized in£uenza virus could be inhib-
ited partially by mannose suggesting that part of the
interaction between the virus and SP-A involves the
carbohydrate binding propensity of this collectin. In-
terestingly, MBP binding to in£uenza virus is more
successfully competed for by mannose and more de-
pendent on Ca2 than SP-A binding. The virus-medi-
ated agglutination of red blood cells was inhibited by
both collectins [28]. However, compared to the ef-
fects of SP-D on the inhibition of haemagglutination
activity of in£uenza A virus, the e¡ects of SP-A and
MBP were relatively small [29]. A recent study by
Hartshorn and co-workers con¢rmed the relatively
small e¡ect of SP-A, compared to the other collec-
tins, on in£uenza A virus-mediated haemagglutina-
tion [30]. In line with results by other groups it was
observed in this study that SP-A-in£uenza A virus
interactions are not Ca2-dependent and are not de-
pendent on the lectin activity of SP-A. SP-A (and
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MBP) may bind in£uenza virus A (H3N2) partly via
interaction with viral neuraminidase [28]. Benne and
co-workers observed concentration- and time-de-
pendent binding of SP-A to in£uenza A (H3N2) vi-
rus-infected HEp-2 cells [31]. Neither the presence of
mannan nor the presence of heparin could prevent
SP-A binding to the infected cells. Interestingly, re-
moval of the N-linked carbohydrate of SP-A or only
its sialic acid residues completely prevented binding
of SP-A to infected HEp-2 cells. Infection of LLC
(MK2D) cells with in£uenza A (H3N2) virus was
prevented by preincubation of the virus with SP-A
[31]. Viral infectivity was measured by the appear-
ance of viral proteins on the cell surface. After re-
moval of the carbohydrate moiety of SP-A by enzy-
matic digestion with N-glycosidase F, or after
neuraminidase treatment, SP-A no longer prevented
viral infection of the cells. It may be concluded that
SP-A binds to in£uenza A virus via its sialic acid
residues and thereby neutralises the virus. Neither
in£uenza B virus infection of LLC cells nor mumps
virus infection of Vero cells could be prevented by
SP-A, although also for these viruses sialic acid res-
idues function as cellular receptors. Semliki Forest
virus infection of L cells was not a¡ected by SP-A
[31].
In a subsequent study Benne and collaborators
showed that SP-A, but not SP-D, is an opsonin for
in£uenza A (H3N2) virus phagocytosis by rat alveo-
lar macrophages [32]. The association and uptake of
FITC-labelled virus by alveolar macrophages was
studied by £ow cytometry. At 60 Wg/ml SP-A a
3-fold increased association of virus with cells was
observed. Trypan blue quenching studies indicated
that about half of the associated virus was internal-
ized. In£uenza A virus phagocytosis could not be
inhibited in the presence of mannan. In contrast,
removal of the sialic acid residues by neuraminidase
or N-glycosidase F treatment resulted in a complete
inhibition of SP-A-induced phagocytosis [32]. Harts-
horn et al. showed that preincubation of in£uenza A
virus with SP-A enhanced the ability of this virus to
stimulate the respiratory burst of neutrophils. In con-
trast to the other collectins tested SP-A did not pro-
tect neutrophils against virus-induced deactivation
[30].
Some viruses, like human immunode¢ciency virus-
1 (HIV-1), infect alveolar macrophages. The route of
entry could include CD4 or non-CD4 receptor-medi-
ated mechanisms, like SP-A-dependent delivery. In
this way SP-A would function as a Trojan horse. A
recent study by Guay et al. showed that SP-A does
not modulate entry of HIV-1 into alveolar macro-
phages [33]. In contrast, MBP inhibits HIV-1 infec-
tion of U937 monocytoid cells by binding to man-
nose residues on the CD4 binding site of gp120 [34].
Sternberg and co-workers measured SP-A levels in
bronchoalveolar lavage from immunosuppressed,
HIV-positive patients [35]. It was found that
amounts of SP-A were signi¢cantly lower in patients
than in healthy, uninfected volunteers, suggesting
that HIV infection lowers SP-A levels. In contrast,
Phelps and Rose found elevated levels of SP-A in
bronchoalveolar lavage from HIV-infected patients
[36]. However, in this study the fact that these pa-
tients had Pneumocystis carinii pneumonia was not
taken into account. Sternberg et al. showed that in
HIV-positive patients with P. carinii pneumonia
SP-A levels were signi¢cantly higher than in HIV-
positive patients without pneumonia [35]. Other ad-
ditional infections of HIV-infected patients did not
have such a dramatic e¡ect on SP-A levels. In line
with these results are observations done in a rat in-
fection model. Experimental infections of rats with
P. carinii carinii resulted in dramatically elevated
SP-A levels in whole lungs [37]. Moreover, Williams
and collaborators observed that isolated P. carinii
from infected rats contained SP-A [38]. In contrast
with the results of Sternberg et al., Downing and co-
workers demonstrated that in bronchoalveolar lav-
age from HIV-infected individuals without evidence
of opportunistic pulmonary infection SP-A levels
were markedly increased compared with normal con-
trol individuals [39].
It is good to realize that determination of the
amounts of SP-A and other surfactant components
in bronchoalveolar lavage as markers for (infectious)
disease can lead to wrong conclusions. In general,
SP-A levels are determined in cell-free lavage £uid
and are expressed as amounts per ml lavage £uid.
Most investigators do not measure amounts of
SP-A in the cellular pellet. However, it is easy to
see that, during infections, secreted SP-A may dis-
tribute di¡erently between the extracellular compart-
ments. SP-A, bound to some pathogens, may deliver
these pathogens to alveolar macrophages resulting in
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the presence of more SP-A in the cellular pellet. In
addition, aggregates of SP-A and SP-D with patho-
gens may pellet at low gravitational forces, also lead-
ing to lower levels of these surfactant proteins in cell-
free lavage £uid. The fact that during P. carinii pneu-
monia SP-A levels were signi¢cantly higher than in
HIV-positive patients with other additional infec-
tions [35] could be related to the observation that
part of the P. carinii clusters (and SP-A, bound to
these clusters) remained in the supernatant. It is clear
that slightly di¡erent lavage and centrifugation tech-
niques could lead to altered recoveries of collectins in
bronchoalveolar lavage £uid and this could also lead
to discrepancies as found between the study of Stern-
berg et al. [35] and that of Phelps and Rose [36].
Furthermore, altered binding of surfactant proteins
to the epithelial surface may also lead to di¡erent
levels of these proteins in retrieved lavage £uid. Since
part of the interactions of SP-A and SP-D with
pathogens and cells is mediated by Ca2-dependent
carbohydrate binding, lavage in the presence of
Ca2-chelators may increase the yield of these collec-
tins in cell-free lavage £uid. However, this will not
release all bound collectins and certainly not inter-
nalized SP-A and SP-D. Finally, it is important to
realize that, measurement of the altered dynamics of
the collectin-dependent defence system during an in-
fectious challenge is probably more informative than
the measurement of collectin levels. For diagnostic
purposes the levels of surfactant components, if
measured both in cell-free lavage and in the (cell)
pellet, will continue to be very valuable.
Fig. 2. Interactions of SP-A and SP-D with bacteria and LPS. SP-A acts as an opsonin and mediates uptake of bacteria by alveolar
macrophages. SP-A binds lipopolysaccharide (LPS), possibly via its lipid A moiety. In contrast, SP-D binds, and possibly aggregates,
LPS via its core polysaccharides and/or O-speci¢c antigens. SP-D agglutinates bacteria.
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4. Interactions of SP-A with bacteria
SP-A interacts with a variety of bacteria and en-
hances uptake of some of these bacteria by phago-
cytic cells (Fig. 2). In an early study Van Iwaarden
and co-workers demonstrated that SP-A from hu-
man alveolar proteinosis patients stimulates phago-
cytosis of radiolabelled, serum-opsonized, Staphylo-
coccus aureus by rat alveolar macrophages in a
surface phagocytosis assay [40]. Rat surfactant also
stimulates phagocytosis in the same assay system and
SP-A is the component responsible for this activity.
SP-A alone had no e¡ect on the phagocytosis of
S. aureus by alveolar macrophages, indicating that
SP-A may stimulate complement and immunoglobu-
lin mediated phagocytosis. No direct binding of
SP-A to S. aureus was reported. Later studies indi-
cated that SP-A binds to S. aureus [41,42] and may
act as an opsonin. In line with the observations of
Van Iwaarden et al. it was reported that phagocyto-
sis of complement and IgG coated erythrocytes is
enhanced if macrophages are cultured on SP-A
coated plates [43]. These early studies indicated that
SP-A may facilitate complement and immunoglobu-
lin-mediated phagocytosis by alveolar macrophages.
In addition, SP-A-enhanced phagocytosis of non-
opsonized bacteria by alveolar macrophages was also
reported [44]. Human SP-A (recombinant and from
alveolar proteinosis patients) was found to stimulate
serum-independent phagocytosis of Escherichia coli,
Pseudomonas aeruginosa and S. aureus by rat alveo-
lar macrophages depending on the growth phase of
the bacteria. Further support indicating that SP-A
itself can act as an opsonin came from the studies
of Pikaar and co-workers. These investigators incu-
bated isolated rat alveolar macrophages with E. coli
in the presence or absence of SP-A. Flow cytometric
studies showed that SP-A enhanced the binding of E.
coli J5 (containing rough LPS) but not of E. coli
O111 (containing smooth LPS) to macrophages, sug-
gesting that SP-A binding to Gram-negative bacteria
is dependent on LPS structure [45]. Electron micro-
scopical studies showed that in the presence of SP-A
the number of ingested J5 bacteria increased nearly
6-fold and the attachment even 20-fold over the con-
trol incubations without SP-A. Preincubation of al-
veolar macrophages with SP-A did not enhance the
binding or uptake of bacteria. Immuno-electron mi-
croscopical studies showed that the attached and in-
gested bacteria were heavily coated with SP-A on
their surface [45]. These observations strongly sug-
gested that SP-A acts as an opsonin in the phagocy-
tosis of bacteria.
SP-A also binds the Gram-positive bacterium S.
aureus [41,42]. McNeeley and Coonrod showed in-
creased attachment of SP-A-coated S. aureus to mac-
rophages without ingestion. SP-A also bound Strep-
tococcus pneumoniae (type 25) in a Ca2-dependent
manner but SP-A-coated pneumococci did not asso-
ciate with macrophages [41]. In contrast to these re-
sults, Tino and Wright recently showed that SP-A
enhances uptake of St. pneumoniae by alveolar mac-
rophages [46]. Furthermore, SP-A was reported to
opsonize S. aureus and to facilitate phagocytosis of
these bacteria by monocytes by binding to the C1q
receptor of these cells [42]. It was found that SP-A
neither binds to, aggregates, nor stimulates the
phagocytosis of Ps. aeruginosa [46]. This result was
not in line with the results from an earlier report [44].
This discrepancy may be explained by the di¡erent
phagocytosis assays employed and by the observa-
tion done in the earlier study [44] that the SP-A-
stimulated phagocytosis varied with the growth
phase of the bacteria. In addition to binding to St.
pneumoniae, Tino and Wright also found that SP-A
binds to Haemophilus in£uenzae and group A Strep-
tococcus. Only H. in£uenzae was aggregated by SP-A
[46]. This indicates that binding, but not aggregation,
is a prerequisite for SP-A-stimulated phagocytosis. In
an earlier report McNeeley and Coonrod already
showed that SP-A binds and aggregates H. in£uenzae
type a and that SP-A promotes attachment and
ingestion of this organism by macrophages [47]. In-
terestingly, SP-A bound much less to H. in£uenzae
type b and SP-A did neither aggregate this organism
nor stimulate uptake by macrophages.
The respiratory pathogen Mycobacterium tubercu-
losis is inhaled into the alveoli of the lung where it is
phagocytosed by and multiplied within mononuclear
phagocytes. Since SP-A stimulates phagocytosis two
studies were devoted to investigate whether M. tuber-
culosis takes advantage of this property of SP-A to
gain access to macrophages. Downing and collabo-
rators observed that bronchoalveolar lavage of HIV-
infected individuals contains a factor which signi¢-
cantly enhanced the attachment of M. tuberculosis to
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murine alveolar macrophages by a factor of 3 rela-
tive to control individuals [39]. This factor turned
out to be SP-A, because the enhancement of M. tu-
berculosis attachment by bronchoalveolar lavage of
HIV-infected individuals could be prevented by im-
munoprecipitation of SP-A from the lavage £uid.
Addition of puri¢ed SP-A to immunoprecipitated
lavage £uid restored the attachment of M. tuberculo-
sis to alveolar macrophages. Furthermore, it was ob-
served that SP-A levels in lavage correlated with M.
tuberculosis attachment, again indicating that M. tu-
berculosis uses SP-A as a Trojan horse. Interestingly,
peripheral CD4 lymphocyte counts of HIV-infected
individuals were inversely proportional to SP-A lev-
els [39]. Gaynor and co-workers obtained evidence
that SP-A enhances phagocytosis of M. tuberculosis
by a direct interaction with human monocyte-derived
macrophages (MDMs) and human alveolar macro-
phages [48]. Removal of SP-A from monolayers of
MDMs by washing before adding bacteria or forma-
tion of MDM monolayers on SP-A coated glass cov-
erslips did not diminish the enhanced adherence of
M. tuberculosis. These experiments suggested that
SP-A may have a direct e¡ect on MDMs as an acti-
vation ligand. Interestingly, deglycosylated human
alveolar proteinosis SP-A and non-glycosylated re-
combinant rat SP-A failed to enhance M. tuberculosis
adherence, suggesting that the carbohydrate moieties
of SP-A may be important in mediating its interac-
tions with MDMs leading to enhanced phagocytosis
of M. tuberculosis. In contrast, boiled human alveo-
lar proteinosis SP-A did not loose its stimulating
activity. It was suggested that SP-A mediates the
reported e¡ect on phagocytosis of M. tuberculosis
via upregulation of the macrophage mannose recep-
tor activity [48].
Recently, it was reported that SP-A also binds to
another mycobacterial species, namely Bacillus Cal-
mette-Gue¤rin [49]. SP-A binds this organism in a
Ca2-dependent manner and binding could be inhib-
ited by the addition of carbohydrates, suggesting that
the CRD is involved in the binding. Complexes of
SP-A with B. Calmette-Gue¤rin were taken up by sev-
eral phagocytic cells via the speci¢c 210 kDa SP-A
receptor [49]. It may be concluded that for this
mycobacterial species SP-A exerts its e¡ect for a
large part as an opsonin rather than by modulating
macrophage function.
The SP-A enhanced phagocytosis of Klebsiella
pneumoniae by alveolar macrophages may occur via
both mechanisms, the opsonizing activity of SP-A,
and the activation of macrophages via an increased
activity of the mannose receptor [50]. Binding of
SP-A to K. pneumoniae was dependent on the strain.
SP-A binds to the capsule of strain K21a (containing
ManK1Man sequences) as was shown by binding of
SP-A-coated particles to the bacterial surface and by
SP-A-induced agglutination of the bacteria. In con-
trast, almost no binding of SP-A to the K2 strain
was observed. In addition, SP-A enhances phagocy-
tosis of K. pneumoniae K21a but not of K2 serotypes
by alveolar macrophages. Pretreatment of macro-
phages with SP-A resulted in the increased binding
and killing of K. pneumoniae K21a [50].
Mycoplasma pulmonis accounts for a large percent-
age of pneumonias and exacerbates other respiratory
conditions such as asthma and chronic obstructive
pulmonary disease. SP-A binds to My. pulmonis in
a concentration and Ca2-dependent manner [51].
Since the binding was not totally dependent on
Ca2, and mannosyl-BSA (up to 2 mM mannose)
was not able to inhibit binding of SP-A to mycoplas-
mas, the authors concluded that the collagen-like
domain of SP-A was involved in binding. However,
additional experiments are required to rule out the
possibility that SP-A binds My. pulmonis via its
CRD. Preincubation of interferon-Q activated murine
alveolar macrophages with SP-A resulted in phago-
cytosis and mycoplasmal killing. SP-A may mediate
killing through generation of NO and/or its toxic
metabolites [51].
SP-A may bind Gram-negative bacteria via inter-
action with its lipopolysaccharides (LPS, endotoxin).
SP-A binds to the J5 mutant of E. coli but not to its
O111 mutant [52]. This suggests that SP-A binds
only to rough LPS, a ¢nding con¢rmed by the bind-
ing of SP-A to LPS-coated beads. LPS binding was
Ca2-dependent. SP-A also bound lipid A-coated
beads. These studies by Van Iwaarden et al. led to
the conclusion that SP-A associates with LPS via the
lipid A moiety of rough LPS and in this way protects
the lung from infection by Gram-negative bacteria
with rough LPS [52]. In contrast, Kalina and co-
workers observed SP-A binding to LPS that was
Ca2-independent [53]. Moreover, these investigators
noticed that SP-A is capable of binding to LPS from
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four di¡erent strains of bacteria and to lipid A. SP-D
was shown to bind to core polysaccharides and/or
O-speci¢c antigens of LPS in a calcium dependent
fashion [54]. In vivo, SP-A and SP-D may act in
concert with other factors to form a complex that
binds Gram-negative bacteria and enhances phago-
cytosis.
The respiratory tract is continuously exposed to
LPS. Therefore, SP-A and SP-D may be involved
in the neutralization and clearance of inhaled free
endotoxin without eliciting an in£ammatory re-
sponse. Indeed, SP-D was shown to act as an endo-
toxin scavenger in a rat model of acute respiratory
distress syndrome (ARDS) [55]. Subsequently, SP-D-
LPS complexes may be taken up by alveolar macro-
phages without macrophage activation. Like bacter-
icidal/permeability increasing protein (BPI) in the
bloodstream SP-D may act to dampen the biological
e¡ects of LPS. However, SP-D may also act like
LPS-binding protein (LBP) which facilitates transfer
of LPS to CD14 on phagocytes and thus enhances
macrophage activation. The role of SP-A in neutral-
izing inhaled endotoxin is not clear either. SP-A lev-
els in lung lavage immediately increase in an acute
phase reaction upon inhalation of LPS [3]. However,
it is not known whether newly secreted SP-A binds
directly to inhaled LPS. Experiments in vitro indi-
cated that the LPS induced secretion of colony-stim-
ulating factors (CSF) by alveolar macrophages and
alveolar type II cells could be blocked by SP-A,
although SP-A alone, like LPS, had a stimulating
e¡ect [53]. It is clear that more work is required to
determine the role of SP-A and SP-D in protecting
the lungs from inhaled endotoxin.
Until recently, most experiments designed to inves-
tigate the role of the collectins SP-A and SP-D in
innate lung defence were carried out in vitro. LeVine
and co-workers reported the ¢rst of a series of stud-
ies in murine infection models using mice lacking SP-
A [56]. SP-A-de¢cient mice were produced by target-
ing the SP-A locus by homologous recombination in
embryonic stem cells [12]. These mice survive nor-
mally under laboratory conditions indicating that
SP-A is not crucial for normal lung function and
suggesting that its role in host defence may be of
importance (see chapter of Korfhagen et al. in this
issue). The studies of LeVine et al. showed, for the
¢rst time, that indeed SP-A-de¢cient mice are more
susceptible to bacterial infections. Intratracheal in-
stillation of group B streptococci resulted in a de-
creased bacterial clearance in SP-A 3/3 mice [56].
The quanti¢cation of bacteria in lung homogenates
indicated that, particularly at 6 h after infection,
bacterial counts were much higher in the SP-A
3/3 mice than in the control mice, indicating that
SP-A is important in immediate, ¢rst-line pulmonary
defence. After 24 and 48 h systemic dissemination of
bacteria was much higher in SP-A 3/3 mice as in-
dicated by a relatively high colony count in the
spleen, whereas almost no bacteria were found in
the spleen of control mice. In line with previous in
vitro studies, LeVine and co-workers obtained evi-
dence that SP-A is involved in the stimulation of
uptake of bacteria by alveolar macrophages. It was
observed that even 48 h after infection fewer bacteria
were associated with alveolar macrophages from SP-
A 3/3 mice than with macrophages from control
mice. Western blot analysis of lung homogenates re-
vealed that SP-D levels apparently did not increase in
response to instillation with group B streptococci
[56].
Using another approach, Herting and collabora-
tors also studied the possibility that SP-A protects
the lung from infection with group B streptococci
[57]. These investigators instilled a rat monoclonal
antibody to rabbit SP-A in the lungs of newborn,
ventilated, near term rabbits, infected the animals
30 min later and determined bacterial proliferation
in these and control animals 5 h after the onset of the
experiment. The control animals received physiolog-
ical saline or nonspeci¢c rat IgG. No signi¢cant dif-
ferences were observed between the bacterial counts
in anti-SP-A-treated rabbits and control animals.
The authors concluded that SP-A is only of limited
importance in host defence against severe neonatal
infections with encapsulated group B streptococci
[57]. However, this conclusion seems to be a little
bit premature since the authors did not show that
the monoclonal antibody to rabbit SP-A indeed
binds to a domain of SP-A that is involved in
host defence. In addition, it was not investigated
whether inoculation with less bacteria resulted in
infections that did not overwhelm SP-A-mediated
lung defence.
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5. Interactions of SP-A with fungi and yeasts
Under normal conditions, fungal infections of the
lungs are rare. Yet, fungi like Cryptococcus neofor-
mans and Aspergillus fumigatus are commonly found
in the environment and are continuously inhaled.
This suggests that e⁄cient defence mechanisms
must exist to protect against these fungi. Cryptococ-
cosis, caused by C. neoformans, occurs mostly in the
immunocompromised host, especially those with de-
fects of cell mediated immunity. It is the leading
mycological cause of death among AIDS patients.
A. fumigatus is one of the major airborne fungi and
causes, depending on the host’s immune status, many
di¡erent diseases, ranging from allergic to invasive
clinical conditions. Schelenz and co-workers pro-
vided the ¢rst evidence that SP-A and SP-D might
be involved in the immediate protection against fun-
gal lung infections [58]. It was found that SP-A and
SP-D bind to the cell wall of acapsular C. neofor-
mans. Two serum collectins, MBP and CL-43, but
not conglutinin, bound to the cell wall of C. neofor-
mans. The CRD is involved in the interaction of
SP-A and SP-D with this fungus. Binding was inhib-
ited in the absence of Ca2 and in the presence of
sugars. The interaction of human SP-A with C. neo-
formans could be e¡ectively inhibited by N-acetyl-
mannosamine and N-acetylglucosamine [58]. In con-
trast, no binding of the collectins was observed with
the encapsulated form of the yeast. SP-D, but not
SP-A causes agglutination of acapsular C. neofor-
mans. In a subsequent study Schelenz presented evi-
dence that SP-A and SP-D bind Aspergillus conidia
of various species [59].
Madan and co-workers conducted a study to ¢nd
out whether SP-A and SP-D enhanced binding,
phagocytosis, activation, and killing of A. fumigatus
conidia by human alveolar macrophages and circu-
lating neutrophils [60]. It was found that both SP-A
and SP-D bound A. fumigatus conidia in a Ca2-
dependent fashion. Mannose and maltose inhibited
binding, mannose being more competitive than mal-
tose for SP-A binding and maltose being more com-
petitive than mannose for SP-D. Interestingly, both
SP-D and SP-A agglutinated conidia and enhanced
binding of conidia to alveolar macrophages and neu-
trophils. In addition, both collectins acted as opso-
nins for the uptake of conidia by neutrophils and
increased oxidative burst and killing of A. fumigatus
conidia. These observations strongly suggested that
both SP-A and SP-D have important roles in host
defence against fungal infections of the lung by en-
hancing uptake of the conidia, increasing activation
of the cellular respiratory burst, and ultimately kill-
ing the infectious pathogens. In a subsequent study,
Madan and co-workers also provided evidence that
SP-A and SP-D play a role in the modulation of
allergic sensitization and/or development of allergic
reactions to the allergens of A. fumigatus (see below).
SP-A did not act as an opsonin for phagocytosis of
Candida albicans by alveolar macrophages [61]. Un-
expectedly, SP-A inhibited the up-regulated phagocy-
tosis of serum-opsonized yeast by alveolar macro-
phages in suspension. C1q and concanavalin A had
a similar e¡ect [61].
P. carinii is also a common cause of life-threaten-
ing pneumonia in immunode¢cient patients. Zimmer-
man and collaborators were the ¢rst to show that the
mannose-rich surface membrane glycoprotein gp120
of P. carinii is a ligand for rat SP-A [62]. Binding of
SP-A to P. carinii is time- and Ca2-dependent and
could be inhibited by mannosyl albumin, indicating
that SP-A binds with its CRD to P. carinii. Further
investigations revealed that rat SP-A binds to the
carbohydrate domains of the major surface glycopro-
tein of P. carinii [63]. Mutant recombinant SP-A
molecules with substitutions for the predicted calci-
um- and carbohydrate-coordinating residues of the
CRD failed to bind to the major surface glycopro-
tein, indicating CRD mediated binding to P. carinii.
The oligosaccharide moiety of SP-A is not required
for the binding of SP-A to the major surface glyco-
protein [63]. In another study it was found that SP-A
enhanced attachment of P. carinii to rat alveolar
macrophage monolayers [38]. SP-A mediated attach-
ment was signi¢cantly reduced in the presence of
EGTA and mannose, but also by type V collagen.
Table 1 gives an overview of the interactions of SP-A
with pathogens.
6. Interactions of SP-A with inhaled glycoconjugates
Since SP-A is a calcium-dependent lectin it can
potentially bind to any inhaled glycoconjugate bear-
ing sugars that can be recognized by SP-A. It is
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conceivable that binding by SP-A (or SP-D) may
a¡ect the fate of the inhaled substance. The ¢rst
study that dealt with SP-A binding to relevant car-
bohydrate containing particles other than pathogens
was the study of Malhotra and co-workers [64].
These investigators showed that SP-A binds to a va-
riety of pollen grains, including pollen from Populus
nigra italica (Lombardy poplar), Poa pratensis (Ken-
tucky blue grass), Secale cerale (cultivated rye) and
Ambrosia elatior (short ragweed) [64]. Interaction of
SP-A with Pop. nigra italica pollen may involve in-
teraction with 57 kDa and 7 kDa glycoproteins since
SP-A binds in a calcium-dependent fashion to aque-
ous extracts of pollen grains containing these pro-
teins. The addition of 50 mM mannose to the micro-
titre plate wells prevented this interaction. Moreover,
calcium-dependent binding to the pollen grains was
lost after aqueous extraction at 4‡C for 48 h. Binding
of SP-A to pollen grains was found to mediate ad-
hesion of pollen grains to A549 cells [64]. Unfortu-
nately, this study is the only study sofar dealing with
collectin binding to plant-derived materials that are
able to elicit an allergic response.
In another study aimed to determine whether SP-
A and SP-D may play a role in the modulation of the
allergic response it was investigated whether these
collectins interact with mite allergens [65]. It was
found that SP-A and SP-D bind to whole mite ex-
tracts (Dermatophagoides pteronyssinus) and the pu-
ri¢ed allergen Der p I in a carbohydrate-speci¢c and
calcium-dependent manner. Der p I is one of the
three major allergens in the faecal pellets of the
house dust mite. SP-A and SP-D did neither bind
to deglycosylated Der p I nor to recombinant forms
of the allergen polypeptides which were expressed in
E. coli in non-glycosylated forms [65]. Finally, it was
demonstrated that SP-A and SP-D inhibit allergen-
speci¢c IgE binding to the mite extract. The precise
nature of this inhibition was not clear. It could be
that the surfactant proteins and IgE share the same
binding site or exert a steric hindrance e¡ect, thus
preventing binding of IgE. The authors concluded
that it is possible that SP-A and SP-D are involved
in the modulation of allergen sensitization and/or the
development of allergic reactions. Recently, investi-
gators from the same group and others provided
evidence that allergen binding by SP-A and SP-D
may be a general phenomenon [66]. It was found
that these collectins bind to the puri¢ed allergens
gp55 and gp45 of the opportunistic fungal pathogen
A. fumigatus in a calcium-dependent fashion. Man-
nose and maltose could partially block binding of
SP-A, respectively SP-D, indicating that the carbohy-
drate binding domain of these collectins was in-
volved. Deglycosylated allergens were not bound.
In line with what was found with mite extracts, SP-
A and SP-D could inhibit the ability of allergen-spe-
ci¢c IgE from Aspergillosis patients to bind to the
allergens. Moreover, both SP-A and SP-D were able
to inhibit A. fumigatus allergen-induced histamine
release from sensitized basophils [66]. Thus, both
SP-A and SP-D may modulate the allergic response
to a wide variety of glycosylated inhaled antigens.
7. SP-A: an acute phase protein?
Intratracheally delivered LPS increased tissue lev-
els of SP-A in rats within 6 h and SP-A levels in
lavage 72 h after administration [67]. Furthermore,
SP-A mRNA levels increased signi¢cantly at 24 h. It
was concluded that SP-A reacted in a manner anal-
ogous to that of mannose-binding protein, a serum-
acute phase reactant. Although these results were in
line with what would be expected, the increase of SP-
A could also be a response to lung injury. Sugahara
and co-workers showed that on the long term intra-
tracheal administration of LPS resulted in a marked
proliferation of alveolar epithelial cells with a con-
Table 1
Pathogens bound by SP-A
Herpes simplex virus type 1 [26,27]
In£uenza A virus (H3N2) [28,31]
S. aureus [41,42]
E. coli J5 [45]
St. pneumoniae [41]
Group A Streptococcus [46]
Group B Streptococcus [56]
H. in£uenzae (type a) [46,47]
M. tuberculosis [39]
B. Calmette-Gue¤rin [49]
K. pneumoniae [50]
My. pulmonis [51]
C. neoformans [58]
A. fumigatus [59,60]
P. carinii [62,63]
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comitant increase of SP-A mRNA [68]. In another
study it was investigated whether SP-A is involved in
the immediate reaction to intratracheally aerosolized
LPS [3]. In this study SP-A levels in lavage were
monitored at short time intervals after LPS admin-
istration. SP-A levels rose sharply within the ¢rst
hour after LPS aerosolization and peaked 10 h after
LPS, indicating that SP-A is involved in the acute
phase reaction to intratracheally aerosolized LPS.
The rapid increase suggested that enhanced secretion
rather than synthesis caused this ‘acute-phase’ behav-
iour [69]. It was not investigated whether type II cells
or Clara cells are responsible for the enhanced secre-
tion. These studies suggest that SP-A (and SP-D) are
involved in the immediate response to infectious
challenge. The ¢rst event may be enhanced secretion
of these collectins, possibly by Clara cells that con-
tain granules ¢lled with SP-A and SP-D [2]. The
second event may be enhanced transcription, result-
ing in a higher production of SP-A and SP-D.
8. Future developments
It may be concluded that SP-A interacts with a
wide variety of pathogens that potentially could in-
fect the lungs. The experiments using mice lacking
SP-A [56] showed, for the ¢rst time, that SP-A may
have an important role preventing lung infections.
Now it is clear that SP-A (and SP-D) are involved
in innate host defence, it is worthwhile to delineate
the mechanisms that regulate collectin-mediated lung
defence upon infectious challenge. It will particularly
be important to determine the relative roles of type II
cells and Clara cells in this defence system. Studies in
vitro and in vivo are required that are aimed to re-
solve the signals (pathogen-derived mediators, cyto-
kines, chemokines, growth factors) involved in the
pro-in£ammatory network that lead to enhanced se-
cretion and production of SP-A and SP-D by epithe-
lial cells. In this respect it is of interest to take into
account that these surfactant proteins may be in-
volved in the intercellular communication between
alveolar macrophages and epithelial cells. Therefore,
it will be necessary to ¢nd out whether these collec-
tins act as pro-in£ammatory mediators. An impor-
tant issue that has not been addressed is the possi-
bility that, in situ, SP-A (and SP-D) may bind
molecules such as C-reactive protein, immunoglobu-
lins, SP-B, proteases, etc., that could exert a variety
of e¡ects. Processes like complement activation,
pathways that link innate defence with the adaptive
immune response, recognition of pathogens, regula-
tion of cell proliferation, etc., could be regulated by
SP-A and SP-D in concert with other proteins.
More support for the role of SP-A in innate lung
defence may come from the genetic screening of pa-
tients with recurrent lung infections, particularly dur-
ing early childhood. This will not be an easy task,
since SP-A is coded by two genes and several allelic
variants have been described. The identi¢cation of
mutations that are correlated with susceptibility to
recurrent infections, and perhaps, the allergic re-
sponse, will help to understand the pathogenesis of
lung disease and the design of adequate ways to treat
patients. In the near future it is of upmost impor-
tance to investigate whether SP-A, SP-D, or hybrid
molecules based on domains of these collectins, are
able to prevent or to treat lung infection in experi-
mental animals. These studies may result in the de-
velopment of drugs based on collectins. Finally, the
expression of SP-A at sites of the body other than
the lung suggests that SP-A-mediated innate defence
may be important at a variety of mucosal surfaces
[70^73]. It will be exciting to establish the role of
surfactant components in tissues other than the lung.
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